StudyFinder
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Status: Recruiting
The goal of this study is to evaluate nemtabrutinib compared with either ibrutinib or acalabrutinib for treatment of people with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• diagnosis of CLL/SLL and with active disease requires therapy
• able to swallow and retain oral medication
• at least capable of all selfcare but may unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:
• active hepatitis B virus/ hepatitis C virus
• history of severe bleeding disorder
• clinically significant cardiovascular disease
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions:
Cancer
Keywords:
chronic lymphocytic leukemia, CLL, SLL, small lymphocytic lymphoma
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Puneet Cheema
Phase: PHASE3
IRB Number: MMCORC093
See this study on ClinicalTrials.gov